Emmaus Medical
  • CEO Letters
  • Overview
    • Mission
    • Leadership
      • Management Team
      • Board of Directors
    • Corporate Compliance
    • Corporate Governance
  • Products
    • Endari
  • Pipeline
    • Research Publications
    • Diverticulosis
    • Cell Sheet Engineering
  • News
    • Press Releases
    • Media Contacts
    • Media Kit
  • Investors
  • Career
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Pre-merger Emmaus Life Science SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Emmaus Life Sciences Announces Presentation of Abstract at the 2018 American Society of Hematology Annual Meeting

Nov 02, 2018 4:15pm EDT

Emmaus Life Sciences, a Leader in Sickle Cell Disease Treatment, to Sponsor the 12th Annual Sickle Cell Disease and Thalassaemia (ASCAT) Conference in London

Oct 22, 2018 12:25pm EDT

Emmaus Life Sciences, a Leader in Sickle Cell Disease Treatment, to Sponsor the 46th Annual National Sickle Cell Disease Association of America Convention in Baltimore

Oct 09, 2018 11:15am EDT

Emmaus Life Sciences to Participate in the Cantor Global Healthcare Conference

Oct 02, 2018 10:26am EDT

Emmaus, a Leader in Sickle Cell Disease Treatment, Signs Agreement with Cardinal Health to Solidify Distribution Network for Endari™ (L-glutamine oral powder)

Sep 19, 2018 9:01am EDT

Emmaus Life Sciences, a Leader in Sickle Cell Disease Treatment, to Present at the Seventh Annual Sickle Cell Disease Therapeutics Conference in New York City on September 13th

Sep 11, 2018 2:03pm EDT

Emmaus, a Leader in Sickle Cell Disease Treatment, Signs Agreement with McKesson to Expand Distribution Network for Endari™ (L-glutamine oral powder)

Aug 27, 2018 8:18am EDT

Emmaus Life Sciences Announces Support of Sickle Cell Disease Legislation

Aug 01, 2018 9:00am EDT

Emmaus Life Sciences Partners with DMS Pharmaceutical Group to Provide Endari™ (L-glutamine oral powder) to Military Personnel and Beneficiaries for Treatment of Sickle Cell Disease

Jul 30, 2018 8:30am EDT

Emmaus Life Sciences Strengthens its Finance & Operations Leadership to Support Commercialization of Endari™

Jul 25, 2018 8:36am EDT
RSS
  • Prev
    • 1...
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Emmaus Medical, Inc. Registered ® Emmaus Medical, Inc, Torrance, CA. All rights reserved.

    • Privacy
    • Terms of Use
    • Contact